- $4.61m
- $6.92m
- $0.01m
Annual balance sheet for Biocorrx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.592 | 0.086 | 0.069 | 0.065 | 0.088 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.225 | 0.058 | 0.166 | 0.077 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 0.975 | 0.228 | 0.317 | 0.187 | 0.118 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.618 | 0.488 | 0.347 | 0.148 | 0.218 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 1.83 | 0.82 | 0.767 | 0.389 | 0.386 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.05 | 4.39 | 5.36 | 6.43 | 8.21 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.92 | 7.66 | 8.84 | 10.2 | 12.5 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -4.09 | -6.84 | -8.08 | -9.82 | -12.1 |
Total Liabilities & Shareholders' Equity | 1.83 | 0.82 | 0.767 | 0.389 | 0.386 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |